Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults

Drug and Alcohol Dependence

Volumn 106, Issue 2-3, 2010, Pages 154-163

  Cherner, Mariana ^a   Suarez, Paola ^a   Casey, Corinna ^a   Deiss, Robert ^a   Letendre, Scott ^b   Marcotte, Thomas ^a   Vaida, Florin ^a   Atkinson, J Hampton ^a,c   Grant, Igor ^a,c   Heaton, Robert K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Veterans Administration   (United States)

Author keywords

Cognitive impairment; Drug exposure; Methamphetamine; Motor impairment; Neuropsychological; Predictors; Stimulant

Indexed keywords

METHAMPHETAMINE;

ADULT; AGE; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BRAIN FUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DEPENDENCE; EDUCATION; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; READING; SELF REPORT;

ADMINISTRATION, ORAL; ADULT; AGE OF ONSET; AMPHETAMINE-RELATED DISORDERS; ATTENTION; COGNITION DISORDERS; EDUCATIONAL STATUS; FEMALE; HUMANS; INJECTIONS; INSUFFLATION; LEARNING; MALE; MEMORY; METHAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; NEUROTOXINS; PREDICTIVE VALUE OF TESTS; SMOKING; SUBSTANCE-RELATED DISORDERS;

HEPATITIS C VIRUS;

EID: 73549109866     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.08.010     Document Type: Article

References (78)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., Mcquillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341 (1999) 556-562
2. Bell J., Batey R.G., Farrell G.C., Crewe E.B., Cunningham A.L., and Byth K. Hepatitis C virus in intravenous drug users. Med. J. Aust. 153 (1990) 274-276
3. Bornstein R.A., Nasrallah H.A., Para M.F., Whitacre C.C., Rosenberger P., and Fass R.J. Neuropsychological performance in symptomatic and asymptomatic HIV infection. AIDS 7 (1993) 519-524
4. Bostwick D.G. Amphetamine induced cerebral vasculitis. Hum. Pathol. 12 (1981) 1031-1033
5. Burrows K.B., and Meshul C.K. High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. Neuroscience 90 (1999) 833-850
6. Cadet J.L., Ali S.F., Rothman R.B., and Epstein C.J. Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Mol. Neurobiol. 11 (1995) 155-163
7. Cahill D.W., Knipp H., and Mosser J. Intracranial hemorrhage with amphetamine abuse. Neurology 31 (1981) 1058-1059
8. Chang L., Ernst T., Speck O., Patel H., Desilva M., Leonido-Yee M., and Miller E.N. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 114 (2002) 65-79
9. Cherner M., Bousman C., Barron D., Letendre S., Everall I., Heaton R., Atkinson J.H., and Grant I. Cytochrome P450 2D6 phenotype and methamphetamine-associated cognitive impairment. J. Int. Neuropsychol. Soc. 14 (2008) 147
10. Cherner M., Letendre S., Heaton R.K., Durelle J., Marquie-Beck J., Gragg B., and Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64 (2005) 1343-1347
11. Cherner M., Masliah E., Ellis R.J., Marcotte T.D., Moore D.J., Grant I., and Heaton R.K. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59 (2002) 1563-1567
12. Ezaki N., Nakamura K., Sekine Y., Thanseem I., Anitha A., Iwata Y., Kawai M., Takebayashi K., Suzuki K., Takei N., Iyo M., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., and Mori N. Short allele of 5-HTTLPR as a risk factor for the development of psychosis in Japanese methamphetamine abusers. Ann. N. Y. Acad. Sci. 1139 (2008) 49-56
13. Finnegan K.T., Ricaurte G., Seiden L.S., and Schuster C.R. Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine. Psychopharmacology (Berl.) 77 (1982) 43-52
14. Frosch D., Shoptaw S., Huber A., Rawson R.A., and Ling W. Sexual HIV risk among gay and bisexual male methamphetamine abusers. J. Subst. Abuse Treat. 13 (1996) 483-486
15. Frost D.O., and Cadet J.L. Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: a hypothesis. Brain Res. Brain Res. Rev. 34 (2000) 103-118
16. Gonzalez R., Rippeth J.D., Carey C.L., Heaton R.K., Moore D.J., Schweinsburg B.C., Cherner M., and Grant I. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend. 76 (2004) 181-190
17. Grant I., Heaton Rk, Mcsweeny A., Adams K., and Timms R.M. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch. Intern. Med. 142 (1982) 1470-1476
18. Halkitis P.N., Parsons J.T., and Stirratt M.J. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J. Homosex. 41 (2001) 17-35
19. Hashimoto T., Hashimoto K., Matsuzawa D., Shimizu E., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., and Iyo M. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 135B (2005) 5-9
20. Hashimoto T., Hashimoto K., Miyatake R., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., and Iyo M. Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 147B (2008) 1040-1046
21. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., and Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 58 (2001) 24-32
22. Heaton R.K., Grant I., Butters N., White D.A., Kirson D., Atkinson J.H., Mccutchan J.A., Taylor M.J., Kelly M.D., Ellis R.J., and The HIV Neurobehavioral Research Center. The HNRC 500-neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1 (1995) 231-251
23. Heaton R.K., Kirson D., Velin R.A., Grant I., and the HNRC Group. The utility of clinical ratings for detecting early cognitive change in HIV infection. In: Grant I., and Martin A. (Eds). Neuropsychology of HIV Infection (1994), Oxford University Press, New York 188-206
24. Hilsabeck R.C., Perry W., and Hassanein T.I. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35 (2002) 440-446
25. Hirata H., and Cadet J.L. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J. Neurochem. 69 (1997) 780-790
26. Hirata H., Ladenheim B., Carlson E., Epstein C., and Cadet J.L. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res. 714 (1996) 95-103
27. Ishikawa A., Kadota T., Kadota K., Matsumura H., and Nakamura S. Essential role of D1 but not D2 receptors in methamphetamine-induced impairment of long-term potentiation in hippocampal-prefrontal cortex pathway. Eur. J. Neurosci. 22 (2005) 1713-1719
28. Itoh K., Hashimoto K., Shimizu E., Sekine Y., Ozaki N., Inada T., Harano M., Iwata N., Komiyama T., Yamada M., Sora I., Nakata K., Ujike H., and Iyo M. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 132B (2005) 70-73
29. Iwata N., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H., and Ozaki N. No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: a collaborative study by the Japanese Genetics Initiative For Drug Abuse. Ann. N. Y. Acad. Sci. 1025 (2004) 34-38
30. Johanson C.E., Frey K.A., Lundahl L.H., Keenan P., Lockhart N., Roll J., Galloway G.P., Koeppe R.A., Kilbourn M.R., Robbins T., and Schuster C.R. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl.) 185 (2006) 327-338
31. Kalechstein A.D., Newton T.F., and Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J. Neuropsychiatry Clin. Neurosci. 15 (2003) 215-220
32. Kanahara N., Miyatake R., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M., and Hashimoto K. Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 150B (2009) 233-238
33. Kinoshita Y., Ikeda M., Ujike H., Kitajima T., Yamanouchi Y., Aleksic B., Kishi T., Kawashima K., Ohkouchi T., Ozaki N., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iyo M., Sora I., and Iwata N. Association study of the calcineurin A gamma subunit gene (PPP3CC) and methamphetamine-use disorder in a Japanese population. Ann. N. Y. Acad. Sci. 1139 (2008) 57-62
34. Kish S.J., Fitzmaurice P.S., Boileau I., Schmunk G.A., Ang L.C., Furukawa Y., Chang L.J., Wickham D.J., Sherwin A., and Tong J. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl.) 202 (2009) 649-661
35. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., and Iwata N. Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. Ann. N. Y. Acad. Sci. 1139 (2008) 70-82
36. Kuczenski R., Everall I.P., Crews L., Adame A., Grant I., and Masliah E. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 207 (2007) 42-51
37. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22 (2002) 8951-8960
38. Lawton-Craddock A., Nixon S.J., and Tivis R. Cognitive efficiency in stimulant abusers with and without alcohol dependence. Alcohol Clin. Exp. Res. 27 (2003) 457-464
39. Letendre S., Marquie-Beck J., Singh K.K., De Almeida S., Zimmerman J., Spector S.A., Grant I., and Ellis R. The monocyte chemotactic protein-1-2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J. Neuroimmunol. 157 (2004) 193-196
40. Manly J.J., Jacobs D.M., Touradji P., Small S.A., and Stern Y. Reading level attenuates differences in neuropsychological test performance between African American and White elders. J. Int. Neuropsychol. Soc. 8 (2002) 341-348
41. Marshall J.F., O'dell S.J., and Weihmuller F.B. Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J. Neural. Transm. Gen. Sect. 91 (1993) 241-254
42. Masliah E., Heaton R.K., Marcotte T.D., Ellis R.J., Wiley C.A., Mallory M., Achim C.L., Mccutchan J.A., Nelson J.A., Atkinson J.H., and Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 42 (1997) 963-972
43. Mccann U.D., Kuwabara H., Kumar A., Palermo M., Abbey R., Brasic J., Ye W., Alexander M., Dannals R.F., Wong D.F., and Ricaurte G.A. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62 (2008) 91-100
44. McKetin R., and Mattick R.P. Attention and memory in illicit amphetamine users. Drug Alcohol Depend. 48 (1997) 235-242
45. McKetin R., and Mattick R.P. Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend. 50 (1998) 181-184
46. Nakamura K., Sekine Y., Takei N., Iwata Y., Suzuki K., Anitha A., Inada T., Harano M., Komiyama T., Yamada M., Iwata N., Iyo M., Sora I., Ozaki N., Ujike H., and Mori N. An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis. Neurosci. Lett. 455 (2009) 120-123
47. Nordahl T.E., Salo R., and Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin. Neurosci. 15 (2003) 317-325
48. Ohgake S., Hashimoto K., Shimizu E., Koizumi H., Okamura N., Koike K., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Shirayama Y., and Iyo M. Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict. Biol. 10 (2005) 145-148
49. Paulus M.P., Hozack N., Frank L., Brown G.G., and Schuckit M.A. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol. Psychiatry 53 (2003) 65-74
50. Pu C., Broening H.W., and Vorhees C.V. Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse 23 (1996) 328-334
51. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., and Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235 (1982) 93-103
52. Ricaurte G.A., Schuster C.R., and Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193 (1980) 153-163
53. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., Wolfson T., and Grant I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 10 (2004) 1-14
54. Robins L.N., Helzer J.E., Croughan J.L., and Ratcliff K.S. National Institute of Mental Health diagnostic interview schedule: its history, characteristics, and validity. Arch. Gen. Psychiatry 38 (1981) 381-389
55. Rogers R.D., Everitt B.J., Baldacchino A., Blackshaw A.J., Swainson R., Wynne K., Baker N.B., Hunter J., Carthy T., Booker E., London M., Deakin J.F., Sahakian B.J., and Robbins T.W. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20 (1999) 322-339
56. Rumbaugh C.L., Bergeron R.T., Fang H.C., and Mccormick R. Cerebral angiographic changes in the drug abuse patient. Radiology 101 (1971) 335-344
57. Salo R., Nordahl T.E., Possin K., Leamon M., Gibson D.R., Galloway G.P., Flynn N.M., Henik A., Pfefferbaum A., and Sullivan E.V. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res. 111 (2002) 65-74
58. Satz P., Morgenstern H., Miller E.N., Selnes O.A., Mcarthur J.C., Cohen B.A., Wesch J., Becker J.T., Jacobson L., D'elia L.F., et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS). J. Acquir. Immune Defic. Syndr. 6 (1993) 503-511
59. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., and Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev. 17 (2007) 275-297
60. Segal D.S., Kuczenski R., O'neil M.L., Melega W.P., and Cho A.K. Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl.) 180 (2005) 501-512
61. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., Okada H., Minabe Y., Suzuki K., Iwata Y., Tsuchiya K.J., Tsukada H., Iyo M., and Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 63 (2006) 90-100
62. Sim T., Simon S.L., Domier C.P., Richardson K., Rawson R.A., and Ling W. Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J. Addict. Dis. 21 (2002) 75-89
63. Simon S.L., Dacey J., Glynn S., Rawson R., and Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J. Subst. Abuse Treat. 27 (2004) 59-66
64. Simon S.L., Domier C., Carnell J., Brethen P., Rawson R., and Ling W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 9 (2000) 222-231
65. Simon S.L., Domier C.P., Sim T., Richardson K., Rawson R.A., and Ling W. Cognitive performance of current methamphetamine and cocaine abusers. J. Addict. Dis. 21 (2002) 61-74
66. Spitzer R.L., Williams J.B.W., Gibbon M., and First M. Structured Clinical Interview for DSM-IV (1995), American Psychiatric Press, Washington, DC
67. Stephans S., and Yamamoto B. Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 72 (1996) 593-600
68. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc. 8 (2002) 448-460
69. Suzuki A., Nakamura K., Sekine Y., Minabe Y., Takei N., Suzuki K., Iwata Y., Kawai M., Takebayashi K., Matsuzaki H., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., and Mori N. An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr. Genet. 16 (2006) 133-138
70. Toomey R., Lyons M.J., Eisen S.A., Xian H., Chantarujikapong S., Seidman L.J., Faraone S.V., and Tsuang M.T. A twin study of the neuropsychological consequences of stimulant abuse. Arch. Gen. Psychiatry 60 (2003) 303-310
71. Trites R.L., et al. Neuropsychologic and psychosocial antecedents and chronic effects of prolonged use of solvents and methamphetamine. I. Group profiles. Psychiatric J. Univ. Ottawa 1 (1976) 14-20
72. Trites R.L., Suh M., Offord D., Nieman G., and Preston D. Neuropsychological and psychosocial antecedents and chronic effects of prolonged use of solvents and methamphetamines. Proceedings of the International Psychiatric Research Society (1974)
73. Ujike H., Sakai A., Nakata K., Tanaka Y., Kodaka T., Okahisa Y., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., and Kuroda S. Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1074 (2006) 90-96
74. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., and Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21 (2001) 9414-9418
75. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., and Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158 (2001) 377-382
76. Woods S.P., Rippeth J.D., Frol A.B., Levy J.K., Ryan E., Soukup V.M., Hinkin C.H., Lazzaretto D., Cherner M., Marcotte T.D., Gelman B.B., Morgello S., Singer E.J., Grant I., and Heaton R.K. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J. Clin. Exp. Neuropsychol. 26 (2004) 759-778
77. Yamamoto B.K., and Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287 (1998) 107-114
78. Yen D.J., Wang S.J., Ju T.H., Chen C.C., Liao K.K., Fuh J.L., and Hu H.H. Stroke associated with methamphetamine inhalation. Eur. Neurol. 34 (1994) 16-22